Risk of Significant Infection in Rheumatoid Arthritis Patients Switching Anti-Tumor Necrosis Factor-α Drugs

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 2, 2012, Pages 119-126

  Nguyen Khoa, Bao Anh ^a   Goehring, Earl L ^a   Alexander, Kimberly A ^b   Dong, Wei ^b   Napalkov, Pavel ^b   Jones, Judith K ^a  

^a The Degge Group Ltd   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRONCHITIS; CAUSAL ATTRIBUTION; CELLULITIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; KIDNEY INFECTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPTICEMIA; SOFT TISSUE INFECTION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; COMORBIDITY; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INJECTIONS, INTRAVENOUS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84866478815     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.04.001     Document Type: Article

References (18)

1. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 2006, 33:2398-2408.
2. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
3. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:1125-1133.
4. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
5. Schneeweiss S., Setoguchi S., Weinblatt M.E., Katz J.N., Avorn J., Sax P.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:1754-1764.
6. Curtis J.R., Xie F., Chen L., Baddley J.W., Beukelman T., Saag K.G., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011, 70(8):1401-1406.
7. Bonilla Trejos E., Hannon M.J., Skanderson M., Good C., Kwoh C.K. Risk of infection in rheumatoid arthritis associated with use of anti-TNF agents, DMARDs and/or prednisone [Abstract 2058]. Arthritis Rheum 2009, 60:S771.
8. Thomson Reuters Web Site Epidemiology Research: Marketscan Research Databases, (accessed March 4, 2012). http://thomsonreuters.com/products_services/healthcare/healthcare_products/pharmaceuticals/epidemiology_resch/.
9. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
10. D'Hoore W., Sicotte C., Tilquin C. Risk adjustment in outcome assessment: The Charlson comorbidity index. Methods Inf Med 1993, 32:382-387.
11. Dixon W.G., Symmons D.P., Lunt M., Watson K.D., Hyrich K.L., Silman A.J., et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56:2896-2904.
12. Dixon W., Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection?. Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther 2006, 8:111.
13. Genovese M.C., Breedveld F.C., Emery P., Cohen S., Keystone E., Matteson E.L., et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009, 68(12):1894-1897.
14. Curtis J.R., Xi J., Patkar N., Xie A., Saag K.G., Martin C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:4226-4227.
15. Salliot C., Gossec L., Ruyssen-Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients. Rheumatol Oxf Engl 2007, 46:327-334.
16. Burmester G.R., Mariette X., Montecucco C., Monteagudo-Sáez I., Malaise M., Tzioufas A.G., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The research in active rheumatoid arthritis (ReAct) trial. Ann Rheum Dis 2007, 66:732-739.
17. Favalli E.G., Desiati F., Atzeni F., Sarzi-Puttini P., Caporali R., Pallavicini F.B., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:266-273.
18. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.